Metabolite identification and metabolic pathway analysis of pirtobrutinib in rats

ZHANG Meijuan; LI Jie; YIN Hang; HOU Mengyu; LI Jiangshuo; WU Jingxuan; DONG Ruihua

doi:10.6039/j.issn.1001-0408.2025.09.10

您当前的位置：

首页 >

文章列表页 >

Metabolite identification and metabolic pathway analysis of pirtobrutinib in rats

更新时间：2025-09-23

- Metabolite identification and metabolic pathway analysis of pirtobrutinib in rats
- ZHONGGUO YAOFANG Vol. 36, Issue 9, Pages: 1076-1081(2025)
- 作者机构：
  
  1.首都医科大学附属北京友谊医院研究型病房，北京　100050
  2.北京中医药大学中药学院，北京　102488
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.09.10
  CLC： R969.1;R917
- Received：10 December 2024，
  
  Revised：2025-03-19，
  
  Accepted：20 March 2025，
  
  Published：15 May 2025
- 稿件说明：
移动端阅览
张美娟,李洁,尹航,等.匹妥布替尼在大鼠体内的代谢产物鉴定及代谢途径分析 [J].中国药房,2025,36(09):1076-1081.

ZHANG Meijuan,LI Jie,YIN Hang,et al.Metabolite identification and metabolic pathway analysis of pirtobrutinib in rats[J].ZHONGGUO YAOFANG,2025,36(09):1076-1081.
张美娟,李洁,尹航,等.匹妥布替尼在大鼠体内的代谢产物鉴定及代谢途径分析 [J].中国药房,2025,36(09):1076-1081. DOI： 10.6039/j.issn.1001-0408.2025.09.10.

ZHANG Meijuan,LI Jie,YIN Hang,et al.Metabolite identification and metabolic pathway analysis of pirtobrutinib in rats[J].ZHONGGUO YAOFANG,2025,36(09):1076-1081. DOI： 10.6039/j.issn.1001-0408.2025.09.10.

摘要

目的

分析、鉴定匹妥布替尼（PTN）在大鼠体内的代谢产物，并探讨其在大鼠体内的可能代谢途径。

方法

6只大鼠按照10 mg/kg灌胃PTN混悬液，收集大鼠给药前30 min以及给药后0.25、0.5、1、2、4、6、8、12、24 h的血液和给药前12 h及给药后24 h的尿液和粪便。采用UHPLC-Orbitrap Exploris 240系统联合Compound Discoverer 3.0和Xcalibur 2.0数据分析软件对PTN在大鼠血浆、尿液和粪便中的代谢产物进行结构鉴定与代谢途径分析。

结果

在大鼠生物样本中共鉴定出29种PTN代谢产物，在血浆、尿液和粪便样本中分别鉴定出17、19和22种代谢产物。PTN的代谢途径主要包括氧化、硫酸化、葡萄糖醛酸化等，且其代谢产物多为2种及以上不同代谢形式的组合产物。其中，涉及Ⅰ相代谢反应的产物共计26个（氧化14个、还原/脱氢9个、脱甲基8个、水解5个），涉及Ⅱ相代谢反应的产物共计20个（硫酸化14个、葡萄糖醛酸化8个）。

结论

PTN在大鼠粪便样本中代谢产物种类较多，主要代谢途径为氧化、硫酸化、葡萄糖醛酸化等。

Abstract

OBJECTIVE

To analyze and identify the metabolites of pirtobrutinib （PTN） in rats， and clarify the possible metabolic pathways of PTN in rats.

METHODS

Six rats were intragastrically administered with 10 mg/kg PTN suspension. Blood samples were collected from the rats 30 minutes before administration and at 0.25， 0.5， 1， 2， 4， 6， 8， 12， 24 hours after administration. Urine and feces samples were collected 12 hours before administration and 24 hours after administration. UHPLC-Orbitrap Exploris 240 system combined with Compound Discoverer 3.0 and Xcalibur 2.0 software were adopted for structural identification and metabolic pathway analysis of PTN metabolites in rat plasma， urine， and feces.

RESULTS

A total of 29 PTN metabolites were identified， including 17， 19 and 22 metabolites in plasma， urine and feces， respectively. The metabolic pathways of PTN mainly included oxidation， sulfation， glucuronidation， etc.， and its metabolites were mostly combination products of two or more different metabolic forms. In detail， a total of 26 metabolites were associated with phase Ⅰ metabolic reactions （14 oxidation metabolites， 9 reduction/dehydrogenation metabolites， 8 demethylation metabolites， and 5 hydrolysis metabolites）. Meanwhile， a total of 20 products were involved in phase Ⅱ metabolites （14 sulfation metabolites and 8 glucuronic acid binding metabolites）.

CONCLUSIONS

PTN exhibits a diverse range of metabolites in rat fecal samples， with the primary metabolic pathways being oxidation， sulfation， glucuronidation， and others.

关键词

Keywords

references

GOMEZ E B ， EBATA K ， RANDERIA H S ， et al . Preclinical characterization of pirtobrutinib，a highly selective，noncovalent （reversible） BTK inhibitor [J ] . Blood ， 2023 ， 142 （ 1 ）： 62 - 72 .

LEWIS K L ， CHEAH C Y . Non-covalent BTK inhibitors：the new BTKids on the block for B-cell malignancies [J ] . J Pers Med ， 2021 ， 11 （ 8 ）： 764 .

SHIRLEY M . Bruton tyrosine kinase inhibitors in B-cell malignancies：their use and differential features [J ] . Target Oncol ， 2022 ， 17 （ 1 ）： 69 - 84 .

TELARAJA D ， KASAMON Y L ， COLLAZO J S ， et al . FDA approval summary：pirtobrutinib for relapsed or refractory mantle cell lymphoma [J ] . Clin Cancer Res ， 2024 ， 30 （ 1 ）： 17 - 22 .

MONTOYA S ， THOMPSON M C . Non-covalent Bruton’s tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia [J ] . Cancers （Basel）， 2023 ， 15 （ 14 ）： 3648 .

MAK K K ， EPEMOLU O ， PICHIKA M R . The role of DMPK science in improving pharmaceutical research and development efficiency [J ] . Drug Discov Today ， 2022 ， 27 （ 3 ）： 705 - 729 .

YOKOI T . A new era in the study of individual differences in drug metabolism and pharmacokinetics [J ] . Drug Metab Pharmacokinet . 2013 ， 28 （ 1 ）： 1 - 2 .

WEN B ， ZHU M S . Applications of mass spectrometry in drug metabolism：50 years of progress [J ] . Drug Metab Rev ， 2015 ， 47 （ 1 ）： 71 - 87 .

ZHU M S ， ZHANG H Y ， GRIFFITH HUMPHREYS W . Drug metabolite profiling and identification by high-resolution mass spectrometry [J ] . J Biol Chem ， 2011 ， 286 （ 29 ）： 25419 - 25425 .

ZAMEK-GLISZCZYNSKI M J ， HOFFMASTER K A ， NEZASA K I ， et al . Integration of hepatic drug transpor- ters and phase Ⅱ metabolizing enzymes：mechanisms of hepatic excretion of sulfate，glucuronide，and glutathione metabolites [J ] . Eur J Pharm Sci ， 2006 ， 27 （ 5 ）： 447 - 486 .

谭艳，汤明海，杜蕾蕾，等 . UHPLC-MS/MS研究抗肿瘤化合物E28在不同种属肝微粒体中的代谢产物 [J ] . 中国新药杂志， 2022 ， 31 （ 20 ）： 2044 - 2050 .

梁幼玲，史旭华，白俊其，等 . 采用UHPLC-MS和质量亏损过滤技术分析二苯乙烯苷在大鼠体内的代谢产物和代谢途径 [J ] . 中国药房， 2021 ， 32 （ 6 ）： 675 - 681 .

BAILLIE T A ， RETTIE A E . Role of biotransformation in drug-induced toxicity：influence of intra- and inter-species differences in drug metabolism [J ] . Drug Metab Pharmacokinet ， 2011 ， 26 （ 1 ）： 15 - 29 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on core genes and potential immunological and metabolic mechanisms associated with Tongmai yangxin pills in the treatment of coronary heart disease

Serum metabolomics-based study on the mechanism of action of bergapten in the treatment of liver fibrosis

Study on metabolites derived from Zhideke granules in rats in vivo

Research progress on metabonomics of traditional Chinese medicine in the treatment of ulcerative colitis

UPLC-MS/MS法鉴定五味子酯甲在大鼠体内的代谢产物

Related Author

LU Meijuan

ZHAO Yingqiang

ZHANG Mingyan

GUO Junchi

LU Chengyu

ZHOU Benjie

XIANG Shijian

FU Juxiong

Related Institution

School of Graduate， Tianjin University of Traditional Chinese Medicine

Evidence-based Medicine Center， Tianjin University of Traditional Chinese Medicine

Dept. of Cardiology， the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

School of Pharmacy， Guangdong Medical University

Dept. of Pharmacy， the Seventh Affiliated Hospital of Sun Yat-sen University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰